# A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza

> **NCT04736758** · PHASE2 · COMPLETED · sponsor: **Jiangxi Qingfeng Pharmaceutical Co. Ltd.** · enrollment: 216 (actual)

## Conditions studied

- Influenza

## Interventions

- **DRUG:** GP681 tablet
- **DRUG:** GP681 Simulant

## Key facts

- **NCT ID:** NCT04736758
- **Lead sponsor:** Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-08
- **Primary completion:** 2021-12-18
- **Final completion:** 2021-12-18
- **Target enrollment:** 216 (ACTUAL)
- **Last updated:** 2022-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04736758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04736758, "A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04736758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*